Bristol Myers Squibb (BMY) Free Cash Flow (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Free Cash Flow for 18 consecutive years, with $3.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Free Cash Flow fell 13.16% year-over-year to $3.1 billion in Q2 2026; TTM through Jun 2026 was $11.4 billion, a 21.53% decrease from a year earlier, with the FY2025 full-year figure at $12.8 billion, down 7.87% from the prior year.
• Free Cash Flow was $3.1 billion for Q2 2026 at Bristol Myers Squibb, up from $757.0 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $6.0 billion in Q3 2025 and troughed at $757.0 million in Q1 2026.
• A 5-year average of $3.1 billion and a median of $3.0 billion in 2022 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 72.29% in 2025, down 60.5% in 2025.
• Over 5 years, Free Cash Flow stood at $3.0 billion in 2022, then soared by 32.5% to $3.9 billion in 2023, then rose by 3.54% to $4.1 billion in 2024, then plunged by 60.5% to $1.6 billion in 2025, then jumped by 92.52% to $3.1 billion in 2026.
• The last three Free Cash Flow figures came in at $3.1 billion (Q2 2026), $757.0 million (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.